Taysha Gene Therapies, Inc. (TSHA) saw its stock price soar by 5.33% during intraday trading on Wednesday, following a positive analyst update.
The surge appears to be driven by Cantor Fitzgerald analyst Kristen Kluska maintaining a Buy rating on the stock with a price target of $19, as reported earlier in the day. Such analyst endorsements often boost investor confidence and can lead to increased buying activity.